The results from several genome scans indicate that chromosome 2q21-q33 is likely to contain an autism susceptibility locus. We studied the potential contribution of nine positional and functional candidate genes: TBR-1; GAD1; DLX1; DLX2; cAMP-GEFII; CHN1; ATF2; HOXD1 and NEUROD1. Screening these genes for DNA variants and association analysis using intragenic single nucleotide polymorphisms did not provide evidence for a major role in the aetiology of autism. Four rare nonsynonymous variants were identified, however, in the cAMP-GEFII gene. These variants were present in five families, where they segregate with the autistic phenotype, and were not observed in control individuals. The significance of these variants is unclear, as their low frequency in IMGSAC families does not account for the relatively strong linkage signal at the 2q locus. Further studies are needed to clarify the contribution of cAMP-GEFII gene variants to autism susceptibility. Molecular Psychiatry (2003) 8, 916-924.
Autism (MIM 209850) is a complex neurodevelopmental disorder characterised by impairments in reciprocal social interaction, difficulties with both verbal and nonverbal communication, and the presence of stereotyped behaviours and interests; onset is in the first 3 years of life. In a small percentage of cases, autism is associated with known medical conditions, the strongest associations being with tuberous sclerosis and fragile X syndrome (reviewed by Lamb et al 1 ). For the majority of cases, which do not have a known medical aetiology, there is now compelling evidence from family and twin studies for the importance of genetic factors. 2, 3 The genetic mechanisms predisposing to autism are likely to be complex and heterogeneous, with the involvement of multiple loci acting epistatically. 4, 5 Several genome screens for autism susceptibility loci have found a number of chromosomal regions that show some evidence of linkage. [5] [6] [7] [8] [9] [10] [11] [12] In the genome screen performed by the International Molecular Genetic Study of Autism Consortium (IMGSAC), 6 the 2q21-33 region provided the most significant result, with a multipoint maximum lod score (MLS) of 3.74 at marker D2S2188 in the total sample of 152 affected sib-pairs. 6 The presence of an autism susceptibility locus on chromosome 2q is further supported by the convergence of linkage findings from another three independent genome screens. 7, 9, 13 In addition, a small de novo deletion of 2q32 has been reported in an individual with high functioning autism. 14 In order to identify the autism susceptibility gene at the 2q locus, we are systematically screening functional candidate genes mapping in the region of highest linkage (between markers D2S2370 and D2S364) for the presence of aetiological mutations/ variants.
We report here the analysis of nine candidate genes: T-box Brain 1 (TBR-1); glutamic acid decarboxylase 1 (GAD1); distal-less 1 (DLX1); distal-less 2 (DLX2); cAMP guanine nucleotide exchange factor II (cAMP-GEFII); chimerin 1 (CHN1); activating transcription factor 2 (ATF2); homeo box D1 (HOXD1) and neurogenic differentiation 1 (NEUROD1).
Six of the nine genes studied are transcription factors involved in neuronal differentiation and brain development. TBR-1 15 induces the transcription of genes containing the T-box DNA regulatory element, 16 including reelin (RELN), a gene that is essential for cerebrocortical development. Reelin maps to 7q22, about 3 cM distal to the peak of linkage reported by the IMGSAC, 17 and is itself a candidate gene for autism. 18, 19 Tbr-1 knockout mice show developmental abnormalities in the laminar organisation of cortical neurons, similar to the neuroanatomical defects of the Reeler mice. 20 The pattern of developmental alterations described in the brains of homozygous and heterozygous Reeler mice also show some overlap with the anomalies reported in post-mortem brains of individuals with autism. 21 HOXD1 is a member of the HOXD cluster and is involved in specifying the cytoarchitecture of the developing diencephalon. 22 The NEUROD1 gene encodes for a basic helix-loophelix (bHLH) transcription factor widely expressed during development in the mammalian brain and pancreas. NeuroD1 knockout mice display a malformation of the dentate gyrus, one of the principal structures of the hippocampus, and exhibit spontaneous limbic seizures. 23 ATF2 is a leucine zipper transcription factor, which binds to cAMP-response elements (CREs), forming homodimers or heterodimers with c-jun to stimulate CRE-dependent transcription. 24 The protein also has intrinsic histone acetyltransferase activity, which is modulated by phosphorylation, and has been proposed to activate transcription by direct effects on chromatin components. 25 DLX1 and DLX2 are homeobox-containing genes involved in regulation of forebrain development. Interestingly, a second pair of DLX genes, DLX5/DLX6, maps to the AUTS1 locus in 7q22, 26 and a conserved enhancer in the Dlx5/Dlx6 intergenic region mediates cross-regulatory interactions between the two pairs of genes. 27 It has been established that the DLX genes play an important role in the specification of GABAergic neurons in the telencephalon. 28 GABA is the major inhibitory neurotransmitter and also plays a role in the development and plasticity of the central nervous system (CNS).
Another candidate gene reported in this study is GAD1, which encodes for the 67-kDA isoform of glutamic-acid decarboxylase, the rate-limiting enzyme catalysing the production of GABA. 29 Abnormalities involving the GABA system in autistic children have been described, raising the possibility of a GABA dysfunction in autism susceptibility. 30 Two other candidate genes, cAMP-GEFII and CHN1, encode regulators of monomeric G proteins of the Ras superfamily, which participate in neuronal signal transduction pathways. cAMP-GEFII is a cAMP sensor that modulates signalling pathways dependent on cAMP levels, but independent of protein kinase A (PKA) activation. 31 The gene is strongly expressed in specific regions of developing and mature brain. One of the cAMP-GEFII substrates is Rap1A, a negative regulator of Ras, which is involved in the control of neuronal cell growth and differentiation. cAMP-GEFII also mediates cAMP-dependent, PKA-independent exocytosis through its interaction with the Rab3a effector proteins Rim1 and Rim2. 32 The CHN1 gene encodes n-chimerin, a neuron-specific GTPase activating protein for the Ras-related p21rac protein.
There are two alternatively spliced isoforms of the gene, differing by the presence or absence of a SH2 Nterminal domain. The two isoforms show a distinct cellular and developmental pattern of expression in the brain, suggesting a specialised rac-mediated role in signal transduction mechanisms.
33
To investigate whether these genes may have a role in autism susceptibility, they were systematically screened for sequence variants in a sample of 48 individuals with autism, selected from IMGSAC families contributing to the linkage peak on chromosome 2q. In addition, single nucleotide polymorphisms (SNPs) within the candidate genes were tested for association with autism in the whole IMGSAC sample.
Materials and methods

Families
The identification of families and assessment methods used by the IMGSAC have been previously described. 6 Briefly, in families passing an initial screen, parents were administered the ADI-R 34 and the Vineland Adaptive Behaviour Scales. 35 Potential cases were assessed using the ADOS. 36 Physical examination was undertaken to exclude recognisable medical causes, particularly tuberous sclerosis. Karyotyping was performed when possible on all affected individuals and molecular genetic testing for Fragile X performed on one case per family. Written informed consent was given by all parents/guardians and, where possible, by affected individuals. The study has been reviewed by the relevant ethical committees.
Mutation screening
The localisation, genomic structure and cDNA sequence of human DLX1 were determined by BLAST search of the mouse Dlx1 gene against the human genome sequence. The structures of the remaining genes were available through the UCSC Genome Browser. PCR amplifications were performed in a final volume of 50 ml, containing 40 ng of genomic DNA extracted from blood, 2-3 mM MgCl 2 , 0.2 mM dNTPs, 0.2 mM of each primer and a mixture of 0.9 U Taq Gold Polymerase and 0.05 U Pfu Turbo DNA Polymerase (Stratagene, UK) in a standard KCl buffer. For GC-rich regions, PCR reactions were performed with the addition of 5% DMSO and 100 mM 7-deaza-2 0 -deoxyguanosine-5 0 -triphosphate (Amersham Pharmacia Biotech, UK). A total of 45 cycles were performed with a touchdown protocol (14 cycles of 30 s or 1 min at 951C, 30 s at T1 À0.51C per cycle, 30 s or 1 min at 721C, followed by 25-30 cycles of 30 s or 1 min at 951C, 30 s at T2, 30 s or 1 min at 721C). Primers were designed using the program Primer 3. Sequences and PCR conditions of all primer pairs are available on request from the authors.
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Denaturing high performance liquid chromatography (DHPLC) analysis was carried out using the WAVE TM DNA Fragment Analysis System (Transgenomic). Crude PCR products were subjected to denaturation at 951C for 4 min followed by gradual reannealing from 95 to 251C over 35 min, and were injected into a DNASep R Column. Fragments were eluted at a flow rate of 0.9 ml/min, with the optimum gradient and column temperature calculated for each amplicon using the WAVEMaker 3.4 program.
Analysis of DNA variants identified by DHPLC All of the samples showing a variant DHPLC pattern were sequenced to determine the nature of the heterozygous change. A restriction digest assay was developed for each of the nonsynonymous substitutions, using the following restriction endonucleases: NspI for the nucleotide change in CHN1 exon-13, SphI for TBR-1 exon-4, BtgI for HOXD1 exon-2, BstNI for cAMP-GEFII exon-22, and Bsp1286I for cAMP-GEFII exon-25. The nucleotide changes in cAMP-GEFII exon-5 and exon-21 could not be distinguished by a commercial restriction endonuclease, therefore the following mismatch primers were designed using the program INSIZER : 5 0 GGCTCCTCCTTATGGTGG TA3 0 -5 0 tgaaaacacataccacacgaca3 0 for cAMP-GEFII exon-5 creating a RsaI site, 5 0 GTGGTTGTTTTTAC AGCACCAG3 0 -5 0 ccaaggtgatgcttaccattat3 0 for cAMP-GEFII exon-21 creating a BstNI site. Crude PCR products were digested in a 15 ml reaction with the appropriate enzyme (New England Biolabs, UK) and fragments were separated on 3 : 1 NuSieve GTG agarose (FMCBioproducts) : standard agarose gel. All nonsynonymous changes were tested in all the autistic individuals of the IMGSAC family collection (346 individuals from 169 families) and in a control group of Caucasian individuals (95 males and 95 females from the European Centre for Collection of Animal Cell Cultures, ECACC). For the cAMP-GEFII exon-22 variant, which was found in two autistic families, an additional control group of 170 Caucasian individuals was tested. The four nonsynonymous variants in cAMP-GEFII were tested in an additional collection of 170 autistic individuals from 152 singleton and multiplex families from Germany.
The nucleotide changes in the 5 0 -untranslated regions of CHN1 and DLX2, and the synonymous substitutions in cAMP-GEF II exon-22 and exon-28, were also further analysed. The CHN1 (alpha-1 isoform) exon-1 4 bp deletion was genotyped in 100 IMGSAC autism cases and in 100 control individuals by PCR amplification with the primers 5 0 TAAAGAGAGATGCTGAGTGTTTTG3 0 (labelled with TET fluorescent dye) and 5 0 GCTTCTAAAAAC TTGAGTCTGAACA3 0 , followed by fragment size separation on ABI 377 sequencing machines (Applied Biosystems). The DLX2 exon-1 variant was tested in 24 control individuals by sequencing. The synonymous substitutions in cAMP-GEFII exon-22 and exon-28 were tested in 190 controls by PCR followed 
Genotyping of SNPs and ins/del variants
In all, 11 SNPs and two insertion/deletion variants identified in the candidate gene screening (Table 1b , c marked with footnote a) and three SNPs selected from dbSNP (ATF2 intron-8 ID 277466, ATF2 intron-13 ID 212355, cAMP-GEFII intron-25 ID 729486) were genotyped in 164 Caucasian IMGSAC multiplex families. The 14 SNPs were analysed by PCR followed by restriction digest, as shown in Table 2 . Genotyping of the CGGG insertion in cAMP-GEFII promoter and of the ACC deletion in ATF2 promoter was performed by PCR amplification with 5 0 -HEX fluorescent primers (Table 2) , followed by fragment separation on ABI377 sequencing machines.
Association and linkage disequilibrium analysis
The IMGSAC family data set includes a number of half-siblings and other extended relatives pairs. 17 To Candidate gene studies for autism on chromosome 2q E Bacchelli et al account for this, the pedigree disequilibrium test (PDT) 37 was used to test for association between autism and SNP markers. The PDT is an extension of the transmission disequilibrium test that allows testing for linkage and association in general pedigrees.
The extent of linkage disequilibrium (LD) between the intragenic markers in cAMP-GEFII was studied using Lewontin's standardised measure of disequilibrium D 0 , calculated using the GOLD program. 38 
Results
Mutation screening
A total of 48 unrelated individuals with autism from the IMGSAC family collection were screened for sequence variants using DHPLC. The patients were selected from affected sib-pair families on the basis of sharing either one or two alleles identical by descent (IBD) in the region surrounding the candidate genes, based on flanking microsatellite marker analysis. Primers were designed to cover all exons, intronexon boundaries, and putative promoter regions. A total of 61 sequence variants were identified: six in CHN1; three in DLX1; three in DLX2; four in GAD1; two in TBR1; eight in ATF2; three in HOXD1; five in NEUROD1; and 27 in cAMP-GEFII (Table 1a-c) .
Nonsynonymous DNA variants were tested in a control sample to investigate their frequency in the normal population (Table 1a, b) . Six variants were not present in a large control group, and could represent possible susceptibility mutations: Ile457Met in CHN1; Val356Met in TBR1; Met165Thr, Val646Phe, Gly706Arg and Thr809Ser in cAMP-GEFII. These variants were then tested in all remaining cases from the IMGSAC collection (Table 1a) . Each variant was only found in a single IMGSAC sib-pair family, with the exception of the Gly706Arg substitution in cAMP-GEFII exon 22, which was identified in two families. The two families could have a common ancestor since they are both from USA; in addition, they share a paternal haplotype for all the tested SNPs in cAMP-GEFII and the flanking microsatellite marker D2S2188 (data not shown). The segregation of the six variants within families is shown in Figure 1 .
The missense substitutions Ala45Thr and Pro197-His found in NEUROD1 have been previously described, with similar allele frequencies to those found in our autism sample. 39 The missense substitution Ala296Thr in HOXD1 is a new variant, but it was also found in controls with a comparable allele frequency (Table 1b) .
Rare missense variants in cAMP-GEFII Five autistic families carry missense variants in the cAMP-GEFII gene. These variants segregate with the autism phenotype within the families, with the exception of the Met165Thr variant, transmitted also to a half-brother who does not have autism. The phenotypic characteristics of the affected individuals carrying missense variants in cAMP-GEFII gene are heterogeneous and do not distinguish them from the rest of the sample. Their parents and siblings are currently being assessed for autism-related milder phenotypes.
The cAMP-GEFII gene was further investigated by screening an additional sample of 48 unrelated individuals with autism from the IMGSAC family collection. Four synonymous substitutions and one intronic variant were found, which were unidentified in the previous screening (Table 1c) , but no additional nonsynonymous changes were detected.
An independent sample of 170 autistic individuals from 152 German families was also screened for the 4 cAMP-GEFII missense variants, with negative results.
Other variants
The remaining variants identified in the candidate genes are in intronic regions, untranslated regions, or lead to synonymous substitutions in the translated protein sequence (Table 1c) . Analysis performed using the SPLICEVIEW program revealed no predicted effect of these DNA variants on the Association studies Association analysis was performed using the more informative SNPs identified in the mutation screening (13 SNPs marked with footnote a in Table 1b , c) and three additional SNPs from dbSNP. Eight of the 16 SNPs were within the cAMP-GEFII gene, four within ATF2, and one in HOXD1, NEUROD1, CHN1, and DLX2, respectively. All SNPs were genotyped in 164 Caucasian multiplex families from the IMGSAC collection and tested for association with autism using the pedigree disequilibrium test (PDT). A subgroup of 96 families from the UK was also analysed separately as they may represent a more homogeneous sample. The cAMP-GEFII P1 marker showed a trend towards transmission disequilibrium in the total sample, which was more significant in the UK subgroup (P ¼ 0.035) ( Table 2 ). Analysis of twopoint and three-point haplotypes of flanking markers within the cAMP-GEFII gene provided no significant results. The distribution of LD between intragenic markers in cAMP-GEFII was calculated using the standardised disequilibrium measure D 0 and is shown in Figure 2 .
Discussion
Several linkage studies have provided convincing evidence for the presence of an autism susceptibility locus on chromosome 2q. The identification of the relevant gene represents a challenging task, as the region of interest is broad and contains many genes that could be responsible for the linkage findings. LD mapping can provide a tool to refine the location of the disease locus; however, the power of this approach depends on the allelic architecture of the susceptibility locus and it may be ineffective if a considerable degree of allelic complexity is present. 40 A complementary approach is to screen candidate genes for genetic variation in a sample of affected individuals, in order to identify potential aetiological variants.
We have targeted nine candidate genes located in the interval of highest linkage in the IMGSAC family data set, which are involved in neuronal growth and differentiation, signal transduction and GABA metabolism.
Screening these genes in a group of 48 autistic probands revealed four rare missense mutations in the cAMP-GEFII gene, all segregating in both affected siblings in each family and absent in a large number of control individuals. Two out of the four nonsynonymous variants (Met165Thr and Gly706Arg, the latter present in two families) lead to nonconservative substitutions, which are more likely to alter protein structure. Interestingly, family 189 harbouring the Gly706Arg missense variant also contains two missense mutations in the RELN gene, which were not found in a large control population. The two RELN variants (Val1762Ile and Asn1159Lys) are transmitted from the mother to both affected sibs, 19 while the Gly706Arg variant in cAMP-GEFII gene is transmitted from the father. This observation suggests a possible interactive effect of the cAMP-GEFII and RELN mutations, at least in this family.
The cAMP-GEFII gene is a good candidate for autism given its putative role in the regulation of synaptic vesicle exocytosis, hence the finding of nonsynonymous variants in this gene is interesting. However, their relevance to the autistic phenotype is difficult to establish. The amino acids corresponding to the four variants are conserved in the orthologous proteins of mouse and rat, but only the conservative Thr809Ser change is located in a known functional domain of the protein (the carboxy-terminal RasGEF domain). Further studies will be necessary to determine if these mutations affect protein function. In addition, the low frequency of the four nonsynonymous variants in IMGSAC families does not account for the relatively strong linkage at the 2q locus, and none of the variants was found in an independent German family sample.
It is possible that a more common susceptibility variant in an intron or in a distal regulatory sequence may exist, which has not been identified by our screening. To investigate this possibility, we performed transmission disequilibrium studies using eight intragenic SNPs within the cAMP-GEFII gene. The results did not provide strong evidence of association with autism. However, a G/T substitution in the promoter yielded a P-value of 0.03 in the subgroup of UK families. This variant does not affect any known regulatory sequence. Increased transmission was observed for the frequent allele, suggesting that this SNP is unlikely to have a causal role, but it could be in LD with a nearby susceptibility variant. Replication in independent samples is needed to confirm this result.
The cAMP-GEFII gene encompasses over 300 kb of genomic DNA with an average spacing between the SNPs tested of approximately 42 kb. Inspection of intermarker LD shows that not all marker pairs exhibited a useful level of LD (D 0 40.7), in particular no significant LD is present between the SNPs in introns 3 and 9 (D 0 ¼ 0.17). Therefore, a denser marker grid would be necessary to achieve sufficient power to detect LD across the whole gene.
In conclusion, no strong evidence was found that any of the nine candidate genes described here play a major role in the aetiology of autism. Further studies will be necessary to assess the possible contribution of cAMP-GEFII gene variants in autism susceptibility.
